Ligand Pharmaceuticals, Inc. (LGND)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$317.33-0.45%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put LGND beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 55% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins.
View ManagementExpectations look high — the market is pricing in about 42% growth a year, above the roughly 27% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskLigand’s royalty-rights acquisitions must drive growth despite recent execution volatility. Revenue growth slowed from 34% to negative 32% year over year in Q3 2026. Q3 non-GAAP earnings beat consensus by 88%. LGND trades at 37× P/E versus the 21× peer median. The market is pricing in more growth than our forecast. A 28% next-quarter miss probability and its premium valuation threaten that growth case. Peer multiples imply a price about 42% below where it trades. Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-29. LGND is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 11 analysts currently covering LGND (as of Oct 2026).
Based on 7 Wall Street analysts offering 12-month price targets for LGND in the last 4 months.
Continue this research
Compare LGND with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LGND Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put LGND next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase royalty revenue and reaffirm full-year financial guidance
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $317.33
The last 12 months of price, then the range of analyst 12-month targets from today’s $317.33.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Higher 2026 EPS guidance and substantial planned capital deployment support royalty growth and portfolio expansion.
Advances: Increase royalty revenue and reaffirm full-year financial guidance
Official quarterly earnings call provides material updates on results, guidance, and portfolio objectives.
Advances: Acquire XOMA Royalty to accelerate growth and diversify portfolio
Acquisition diversifies portfolio and accelerates growth.
Advances: Acquire XOMA Royalty to accelerate growth and diversify portfolio
Highlights growth potential from XOMA Royalty acquisition.
Advances: Strategic partnership with XOMA Royalty
Royalty model gains scale supports strategic partnership.
Advances: Reaffirm and raise 2026 financial guidance including EPS and revenue
Reaffirming guidance supports growth expectations for 2026.
